Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

País como asunto
Tipo del documento
Publication year range
1.
S Afr Med J ; 98(2): 105-8, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18350203

RESUMEN

Lipoprotein lipase deficiency causes severe hypertriglyceridaemia due to chylomicronaemia, and leads to recurrent and potentially life-threatening pancreatitis. This disorder can only be managed by dietary fat restriction as drugs are ineffective. We review the experience with familial chylomicronaemia in patients who attended the lipid clinics at Groote Schuur Hospital and Red Cross Children's War Memorial Hospital in Cape Town. Criteria for inclusion were an initial plasma triglyceride concentration of >15 mmol/l and a typical type I Fredrickson hyperlipidaemia pattern on plasma lipoprotein electrophoresis. A total of 29 patients were seen over 25 years. The mean age of presentation was 10 years, but ranged from 0 to 43 years. The modes of presentation differed: pancreatitis (N=16), eruptive xanthomata (N=2), coincidental detection of hypertriglyceridaemia (N=2), screening relatives (N=7), and after death from pancreatitis (N=1). Plasma triglycerides responded rapidly and dramatically to dietary fat restriction, and some patients sustained good control of the hyperlipidaemia. The onset of pancreatitis was earlier in patients of Indian ancestry, suggesting a genotype/phenotype interaction within this disorder. Genetic work-up indicated founder effects in the Afrikaner and Indian patients. Lipaemic plasma should be taken seriously at all ages, and necessitates work-up at specialised clinics where the diagnosis of chylomicronaemia or type I hyperlipidaemia facilitates appropriate dietary management that can prevent pancreatitis.


Asunto(s)
Hiperlipoproteinemia Tipo I/complicaciones , Hiperlipoproteinemia Tipo I/epidemiología , Hipertrigliceridemia/epidemiología , Hipertrigliceridemia/etiología , Adolescente , Adulto , Niño , Preescolar , Dieta con Restricción de Grasas , Femenino , Efecto Fundador , Humanos , Hipertrigliceridemia/terapia , Hallazgos Incidentales , Lactante , Recién Nacido , Masculino , Tamizaje Masivo , Mutación , Pancreatitis/epidemiología , Pancreatitis/etiología , Grupos Raciales , Sudáfrica/epidemiología , Xantomatosis/epidemiología , Xantomatosis/etiología
2.
SAMJ, S. Afr. med. j ; 98(2): 105-108, 2008.
Artículo en Inglés | AIM | ID: biblio-1271394

RESUMEN

Lipoprotein lipase deficiency causes severe hypertriglyceridaemia due to chylomicronaemia and leads to recurrent and potentially life-threatening pancreatitis. This disorder can only be managed by dietary fat restriction as drugs are ineffective.We review the experience with familial chylomicronaemia in patients who attended the lipid clinics at Groote Schuur Hospital and the Red Cross Children's War Memorial Hospital in Cape Town. The criteria for inclusion were an initial plasma triglyceride concentration of 15 mmol/L and a typical type I Fredrickson hyperlipidaemia pattern on plasma lipoprotein electrophoresis. A total of 29 patients were seen over 25 years. The mean age of presentation was 10 years; but ranged from from 0 to 43 years. The modes of presentation differed: pancreatitis (n=16); eruptive xanthomata (n=2); coincidental detection of hypertriglyceridaemia (n=2); screening relatives (n=7) and after death from pancreatitis (n=1). Plasma triglycerides responded rapidly and dramatically to dietary fat restriction and some patients sustained good control of the hyperlipidaemia.. The onset of pancreatitis was earlier in patients of Indian ancestry suggesting a genotype/phenotype interaction within this disorder. Genetic work-up indicated founder effects in the Afrikaner and Indian patients. Lipaemic plasma should be taken seriously at all ages and necessitates work-up at specialised clinics where the diagnosis of chylomicronaemia or type I hyperlipidaemia facilitates appropriate dietary management that can prevent pancreatitis


Asunto(s)
Quilomicrones , Hiperlipoproteinemia Tipo IV/efectos adversos , Lipoproteína Lipasa
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda